| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Special Feature |
Departments of Endocrinology and Metabolism (M.F.P., M.N.G., W.M.W.), Clinical Epidemiology and Biostatistics (C.B.T., F.W.D.), and Radiotherapy (L.Ba.) and Orbital Center (L.Bl.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; and Donders Institute of Ophthalmology (Orbital Unit), University Medical Center (M.P.M.), 3584 CX Utrecht, The Netherlands
Address all correspondence and requests for reprints to: M. F. Prummel, M.D., Ph.D., Departments of Endocrinology and Metabolism, F5-171, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. E-mail: m.f.prummel{at}amc.uva.nl.
Radiotherapy is often used in Graves ophthalmopathy, but its efficacy has been doubted. We compared its efficacy with sham irradiation in mild ophthalmopathy. In a double-blind randomized trial, 44 patients received orbital irradiation, and 44 were sham-irradiated. The primary outcome was assessed using major and minor criteria. As secondary outcome, we used a disease-specific quality of life questionnaire (the GO-QoL) and compared cost-effectiveness and need for follow-up treatment. The primary outcome was successful in 23 of 44 (52%) irradiated patients vs. 12 of 44 (27%) sham-irradiated patients at 12 months after treatment (relative risk, 1.9; 95% confidence interval, 1.13.4; P = 0.02). Radiotherapy was effective in improving eye muscle motility and decreasing the severity of diplopia. However, quality of life improved similarly in both groups. In the radiotherapy group there was less need for follow-up treatment; 66% vs. 84% of the patients needed further treatment (P = 0.049). Retrobulbar irradiation did not prevent worsening of ophthalmopathy, which occurred in 14% of the irradiated and 16% of the sham-irradiated patients. Radiotherapy is an effective treatment in mild ophthalmopathy. However, the improvement upon irradiation may not be associated with an increase in quality of life or a reduction in treatment costs.
This work was supported by a grant from the Dutch Health Care Insurance Board (OG 94/038).
Abbreviations: CI, Confidence interval; GO, Graves ophthalmopathy; GO-QOL, GO quality of life; MOS, Medical Outcomes Study; SIP, Sickness Impact Profile.
This article has been cited by other articles:
![]() |
L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF] |
||||
![]() |
I Coulter, S Frewin, G E Krassas, and P Perros Psychological implications of Graves' orbitopathy Eur. J. Endocrinol., August 1, 2007; 157(2): 127 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Smith B Cell Depletion in Graves' Disease: The Right Answer to the Wrong Question? J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1620 - 1622. [Full Text] [PDF] |
||||
![]() |
T. Cawood, P. Moriarty, and D. O'Shea Recent developments in thyroid eye disease BMJ, August 14, 2004; 329(7462): 385 - 390. [Full Text] [PDF] |
||||
![]() |
L. Bartalena, C. Marcocci, and A. Pinchera Orbital Radiotherapy for Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 13 - 14. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |